logo logo

Telmisartan medication tolerated well

A Canadian study found telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death and heart attack in people who are unable to tolerate normal ACE inhibitor treatment.

Approximately 20% of patients who should be taking ACE inhibitors to lower their blood pressure stop due to side effects such as; cough, kidney problems, swelling or low blood pressure.

Telmisartan study

Telmisartan is a type of angiotensin-receptor blocker, or ARB. ARBs block the receptor sites in the body for angiotensin II, a hormone that increases blood pressure. ARB’s, like ACE inhibitors lower blood pressure.

The TRANSCEND study enrolled 6,000 people worldwide who can’t tolerate ACE inhibitors. The researchers assessed whether telmisartan would reduce the risk of major cardiovascular events.

The results

Telmisartan reduced the outcome by 13% of cardiovascular death, heart attack or stroke. “The TRANSCEND study demonstrates the value of telmisartan in people who are unable to tolerate angiotensin converting enzyme inhibitors.” said researcher Dr. Yusuf from McMaster University.

The researchers wrote, At the present time, ACE inhibitors seem to be the most appropriate first-line agents for patients needing renin-angiotensin-system blockade. Telmisartan may be a reasonable alternative in patients who are intolerant to ACE inhibitors.


bottom KellieMyHS

About Kellie

Kellie is 37 years old and together with her brother Steve makes up the My Health Software team.

She helps on the websites and gathering news for the programs. Kellie worked in the medical industry prior to having her two children (8 and 6) and has a strong interest in self awareness and management of health conditions.


News "home delivered"

Note: These news headlines are now automatically displayed on the home page of the My Health Software applications for Windows.

The news is updated regularly, and you can click through to these items to read more.